FDA Warns of Mortality Signal With Paclitaxel Devices in PAD

Share this post

Preliminary analysis of long-term data finds a 50% increase in risk for mortality in patients treated with paclitaxel-coated devices for peripheral arterial disease.
News Alerts

This post was syndicated from Medscape Medical News Headlines. Click here to read the full text on the original website.

Share this post

Be the first to comment

Leave a Reply